Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.
Next post
Ally Financial draws praise as well-positioned for soft landing in Citi’s new ‘buy’ rating
More Stories
Why Constellation Energy and Vistra shares are building on massive gains
Constellation has a new nuclear-power deal with Microsoft. Both Constellation and Vistra shares have more than doubled this year on...
Why Fed bets were so out of whack: Waller explains what put him ‘over the edge’ for a jumbo rate cut
Inflation might actually fall too far, Fed governor says.
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
‘Powell delivered the stock market to the Promised Land.’ Why the S&P 500 could soar past 6,000 by year-end.
Yardeni: Odds of a 1990s-like market boom have increased after Fed rate-cut.
Small-cap stocks post longest rally since 2021 after Fed rate cut. What’s next?
Small-cap stocks just saw their longest winning streak in three and a half years, after the Federal Reserve recalibrated its...
Traders face biggest index rebalancing in four years on Friday: Here’s what to watch for
Investors are facing the busiest quarterly rebalancing in about four years on Friday in a shakeup that could impact roughly...